Miller‐Fisher syndrome after COVID‐19: neurochemical markers as an early sign of nervous system involvement

Miller‐Fisher syndrome (MFS) is classified as a variant of Guillain–Barré syndrome (GBS), accounting for 5%–25% of all GBS cases. Since the coronavirus disease‐2019 (COVID‐19) outbreak, increasing evidence has been reported of the neurological manifestations of severe acute respiratory syndrome coro...

Descripción completa

Detalles Bibliográficos
Autores principales: Senel, M., Abu‐Rumeileh, S., Michel, D., Garibashvili, T., Althaus, K., Kassubek, J., Otto, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436567/
https://www.ncbi.nlm.nih.gov/pubmed/32781484
http://dx.doi.org/10.1111/ene.14473
_version_ 1783572533902049280
author Senel, M.
Abu‐Rumeileh, S.
Michel, D.
Garibashvili, T.
Althaus, K.
Kassubek, J.
Otto, M.
author_facet Senel, M.
Abu‐Rumeileh, S.
Michel, D.
Garibashvili, T.
Althaus, K.
Kassubek, J.
Otto, M.
author_sort Senel, M.
collection PubMed
description Miller‐Fisher syndrome (MFS) is classified as a variant of Guillain–Barré syndrome (GBS), accounting for 5%–25% of all GBS cases. Since the coronavirus disease‐2019 (COVID‐19) outbreak, increasing evidence has been reported of the neurological manifestations of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, affecting both the central and peripheral nervous system. Here we report the clinical course, detailed cerebrospinal fluid (CSF) profile including CSF/blood antibody status, and neurochemical characteristics of a patient with a typical clinical presentation of MFS after a positive SARS‐CoV‐2 infection test.
format Online
Article
Text
id pubmed-7436567
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-74365672020-08-19 Miller‐Fisher syndrome after COVID‐19: neurochemical markers as an early sign of nervous system involvement Senel, M. Abu‐Rumeileh, S. Michel, D. Garibashvili, T. Althaus, K. Kassubek, J. Otto, M. Eur J Neurol Infectious Diseases Miller‐Fisher syndrome (MFS) is classified as a variant of Guillain–Barré syndrome (GBS), accounting for 5%–25% of all GBS cases. Since the coronavirus disease‐2019 (COVID‐19) outbreak, increasing evidence has been reported of the neurological manifestations of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, affecting both the central and peripheral nervous system. Here we report the clinical course, detailed cerebrospinal fluid (CSF) profile including CSF/blood antibody status, and neurochemical characteristics of a patient with a typical clinical presentation of MFS after a positive SARS‐CoV‐2 infection test. John Wiley and Sons Inc. 2020-10-13 2020-11 /pmc/articles/PMC7436567/ /pubmed/32781484 http://dx.doi.org/10.1111/ene.14473 Text en © 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Infectious Diseases
Senel, M.
Abu‐Rumeileh, S.
Michel, D.
Garibashvili, T.
Althaus, K.
Kassubek, J.
Otto, M.
Miller‐Fisher syndrome after COVID‐19: neurochemical markers as an early sign of nervous system involvement
title Miller‐Fisher syndrome after COVID‐19: neurochemical markers as an early sign of nervous system involvement
title_full Miller‐Fisher syndrome after COVID‐19: neurochemical markers as an early sign of nervous system involvement
title_fullStr Miller‐Fisher syndrome after COVID‐19: neurochemical markers as an early sign of nervous system involvement
title_full_unstemmed Miller‐Fisher syndrome after COVID‐19: neurochemical markers as an early sign of nervous system involvement
title_short Miller‐Fisher syndrome after COVID‐19: neurochemical markers as an early sign of nervous system involvement
title_sort miller‐fisher syndrome after covid‐19: neurochemical markers as an early sign of nervous system involvement
topic Infectious Diseases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436567/
https://www.ncbi.nlm.nih.gov/pubmed/32781484
http://dx.doi.org/10.1111/ene.14473
work_keys_str_mv AT senelm millerfishersyndromeaftercovid19neurochemicalmarkersasanearlysignofnervoussysteminvolvement
AT aburumeilehs millerfishersyndromeaftercovid19neurochemicalmarkersasanearlysignofnervoussysteminvolvement
AT micheld millerfishersyndromeaftercovid19neurochemicalmarkersasanearlysignofnervoussysteminvolvement
AT garibashvilit millerfishersyndromeaftercovid19neurochemicalmarkersasanearlysignofnervoussysteminvolvement
AT althausk millerfishersyndromeaftercovid19neurochemicalmarkersasanearlysignofnervoussysteminvolvement
AT kassubekj millerfishersyndromeaftercovid19neurochemicalmarkersasanearlysignofnervoussysteminvolvement
AT ottom millerfishersyndromeaftercovid19neurochemicalmarkersasanearlysignofnervoussysteminvolvement

Ejemplares similares